Koru Medical Systems, Inc. (NASDAQ: KRMD) saw an increase in internal confidence signals following a recent stock acquisition by its Chief Technology Officer, Eric Schiller. Mr. Schiller purchased 5,000 shares of the company's common stock on May 18, 2026, executing the transaction at a price of $3.9125 per share. This purchase totaled $19,562, and following this activity, Eric Schiller now holds directly 5,000 shares of KORU Medical's common stock.
The timing of this insider buying is notable against the current market performance of KRMD. While the company’s stock trades at $4.00, representing a decline of 32% year-to-date, it had achieved a 34% gain over the preceding twelve months. Independent analysis from InvestingPro suggests that, relative to its Fair Value estimate, the stock may appear overvalued.
Furthermore, insights provided by InvestingPro include an advisory tip noting that KORU Medical is not projected to achieve profitability this year. However, the company maintains a level of liquidity, possessing assets that exceed its short-term obligations. Investors seeking deeper analysis can access additional ProTips and comprehensive financial metrics through the platform’s detailed Pro Research Report.
Beyond the stock activity and valuation notes, KORU Medical Systems recently reported substantial operational achievements for the first quarter of 2026. The company surpassed its revenue projections, generating $11.8 million in revenue. This figure represents a significant year-over-year increase of 22% compared to the same period last year.
In terms of profitability metrics, KORU Medical also met its earnings per share (EPS) forecast, which indicates strong financial execution and operational stability. Complementing these financial results, KORU Medical presented detailed research concerning its FreedomEDGE infusion system at the Oncology Nursing Society Congress. The presentation highlighted successful implementation outcomes and positive patient results for subcutaneous drug administration procedures. Crucially, the study confirmed that all administered doses adhered strictly to established clinical guidelines.
These recent developments collectively underscore KORU Medical’s sustained commitment to advancing innovation within medical technology. The combination of strong quarterly financial performance, reaching key EPS forecasts, and demonstrating clinical efficacy for its specialized infusion systems suggests continuous progress in the sector.